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ABSTRACT:
Background: Hospitalizations due to medical and surgical complications of substance use disorder (SUD)
are rising. Most hospitals lack systems to treat SUD, and most people with SUD do not engage in
treatment after discharge.
Objective: Determine the effect of a hospital-based addiction medicine consult service, the Improving
Addiction Care Team (IMPACT), on post-hospital SUD treatment engagement
Design: Cohort study using multivariable analysis of Oregon Medicaid claims comparing IMPACT patients
with propensity-matched controls.
Participants: 18-64 year-old Oregon Medicaid beneficiaries with SUD, hospitalized at an Oregon hospital
between July 1, 2015 and September 30, 2016. IMPACT patients (n=208) were matched to controls
(n=416) using a propensity score that accounted for SUD, gender, age, race, residence region, and
diagnoses.
Interventions: IMPACT included hospital-based consultation care from an interdisciplinary team of
addiction medicine physicians, social workers, and peers with lived experience in recovery. IMPACT met
patients during hospitalization; offered pharmacotherapy, behavioral treatments, and harm reduction
services; and supported linkages to SUD treatment after discharge.
Outcomes: Healthcare Effectiveness Data and Information Set (HEDIS) measure of SUD treatment
engagement, defined as two or more claims on two separate days for SUD care within 34 days of
discharge.
Results: Only 17.2% of all patients were engaged in SUD treatment before hospitalization. IMPACT
patients engaged in SUD treatment following discharge more frequently than controls (38.9% vs. 23.3%,
p<0.01; aOR 2.15, 95% Confidence Interval [CI] 1.29-3.58). IMPACT participation remained associated
with SUD treatment engagement when limiting the sample to people who were not engaged in
treatment prior to hospitalization (aOR 2.63; 95% CI 1.46-4.72).
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Conclusions: Hospital-based addiction medicine consultation can improve SUD treatment engagement,
which is associated with reduced substance use, mortality, and other important clinical outcomes.
National expansion of such models represents an opportunity to address an enduring gap in the SUD
treatment continuum.
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INTRODUCTION
Hospitals are increasingly filled with people suffering from medical complications of substance use
disorders (SUD) (1, 2). One in seven patients in general hospitals have a substance use disorder (3) and
hospitalizations for opioid- and methamphetamine-related diagnoses are surging (4-6). Patients with
SUD have longer lengths of stay, higher costs (6), and higher readmission rates (3). Over the last decade,
costs related to SUD-associated hospitalizations have quadrupled, with an estimated $15 billion due to
hospitalizations related to opioid use disorder in 2012 alone (2).

Despite frequent hospitalizations and high healthcare costs, most hospitalized patients with SUD are not
engaged in SUD care before hospitalization, and most hospitals do not treat SUD during the acute
inpatient encounter (2, 7). Failure to treat SUD in hospitals leads to untreated withdrawal, failure to
complete recommended medical therapy, and high rates of against medical advice discharge (8-10).
Though there are decades of evidence showing the effectiveness of medication for opioid (11) and
alcohol use disorders (12), most hospitals lack expertise and systems to treat SUD and do not effectively
connect people to treatment after discharge (13). Barriers include lack of addiction medicine expertise,
regulatory concerns, stigma, and silos between hospital and community SUD treatment settings (8, 14).

Hospitalization is a crucial potential juncture to engage out-of-treatment adults in SUD care (15, 16).
Hospitalized patients with SUD have nearly twice the rate of hospital readmission and repeat ED use
within 30 days (3), compared to those without SUD. And the immediate period after hospital discharge
is particularly high risk for drug-related death and suicide (17). SUD treatment engagement is associated
with reduced substance use severity (18-21), higher employment and wages (22), less future criminal
involvement (21), reduced overdose rates (11), and reduced all-cause mortality (11, 23). Hospitalization
can be a reachable moment to initiate and coordinate SUD care. Although medical and surgical
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inpatients do not come to the hospital seeking addiction care, a study of hospitalized adults at our
hospital found that over half of people with high-risk alcohol use and over two-thirds of people with
high-risk drug use reported wanting to cut back or quit (24). Interventions to improve post-discharge
SUD treatment engagement are likely to improve outcomes for people with SUD.

Despite a growing literature of the feasibility and importance of hospital-based addictions care (25-29),
there are no studies using robust causal inference methods to evaluate the effects of inpatient addiction
medicine consultation on SUD treatment engagement after discharge. A quasi-experimental study at a
single Boston academic medical center comparing patients who received inpatient addiction medicine
consultation with those who did not found that patients seen by the consult service were more likely to
report SUD treatment engagement at 30 and 90 days after discharge (30). While promising, this study
relied on self-reported outcomes and had 34% loss-to follow up at 30 days and 47% at 90 days.
Additional rigorous evaluations to understand the effect of hospital-based addiction medicine care on
post-hospital community SUD treatment are critical for broader adoption and dissemination.

We implemented a previously described interprofessional hospital-based addiction medicine consult
service called the Improving Addiction Care Team (IMPACT) (8, 24, 31, 32). IMPACT engages adults with
opioid, alcohol, methamphetamine, and other substances (excluding tobacco use disorder alone) during
the reachable moment of hospitalization and provides rapid-access pathways to community SUD
treatment and harm reduction support. The goal of this analysis was to assess post-hospital SUD
treatment engagement among Oregon Medicaid recipients who received IMPACT care compared to
propensity score-matched controls. We hypothesized that IMPACT participation would be associated
with greater post-hospital SUD treatment engagement.
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METHODS
Intervention
IMPACT is a hospital-based addiction medicine consult service that includes care from addiction
medicine physicians, social workers, and peers with lived experience in recovery. Inpatient medical and
surgical providers and hospital social workers refer patients with known or suspected SUD to IMPACT.
IMPACT is open to patients with any SUD (excluding people with tobacco use disorders alone) regardless
of readiness to change or interest in treatment. Initially IMPACT served patients admitted to medicine,
family medicine, cardiology services; or patients needing prolonged intravenous antibiotics admitted to
any hospital service. IMPACT expanded to include surgical services in July 2017. IMPACT medical
providers and social workers perform an initial comprehensive assessment, including DSM-5 SUD
diagnosis assessment; elicit patient-centered goals around the acute hospitalization and SUD; initiate
SUD treatment, including pharmacotherapy and behavioral treatments; and offer harm reduction
services. IMPACT includes robust referral pathways to post-hospital SUD care and, in some cases, forges
relationships with rural SUD providers to coordinate post-hospital care (24, 31, 32). Earlier work
provides a detailed description of the interprofessional team and intervention (24, 32).

During the study window, IMPACT included 0.7 full-time equivalent (FTE) clinical physician time shared
amongst 5 physicians, 1 social worker, and 2 peer recovery mentors. IMPACT physicians documented a
median value of 2 patient visits (range 1-33) and social workers a median 3 (1-33) patient visits per
hospitalization. Intervention intensity depends on patient needs, hospital length-of-stay, and IMPACT
capacity.

Setting and study design:
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Earlier research found that IMPACT created system-level change by reframing addiction as a treatable
chronic disease, increasing provider understanding of how to engage and treat patients with SUD, and
creating rapid pathways to care (8). As such, a patient- or provider- level randomized trial would not
adequately isolate the intervention effect. Thus, we conducted a multivariable analysis comparing
intervention patients to propensity-matched controls across Oregon hospitals. We used Oregon
Medicaid claims data, obtained under a data use agreement with the Oregon Health Authority, that
included physical/behavioral health and pharmacy claims in calendar years 2015-2016. This study was
approved by the Oregon Health & Science University (OHSU) Institutional Review Board.

Population
All participants were 18-64 years-old with Oregon Medicaid insurance, had at least one SUD diagnosis
(not including tobacco use disorder), and were hospitalized at an Oregon hospital between July 1, 2015
and September 30, 2016. IMPACT patients had confirmed or suspected SUD and were referred by
medical and surgical providers at a large academic center in Portland, Oregon. Interest in SUD treatment
was not required for IMPACT participation. Patients initially referred for IMPACT evaluation were
excluded if a DSM-5 SUD diagnosis was not confirmed. We included individuals with past SUD treatment
because acute illness and hospitalization can interrupt SUD treatment (33) and precipitate return to use,
and IMPACT coordinates and supports care continuity for hospitalized patients already engaged in
treatment. During the study window, IMPACT had 357 referrals. Of those, 269 (75.3%) had Oregon
Medicaid, of which 264 were eligible for IMPACT and 208 were seen by IMPACT and comprise the
IMPACT cohort (Figure 1).

We used propensity score matching to reduce bias by ensuring that cases and controls had comparable
covariate distributions (34). First, we calculated a propensity score using all inpatient admissions with an
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SUD diagnosis. We calculated a propensity score using backwards stepwise logistic regression and
accounted for SUD type, gender, age, race, residence region, and diagnoses, including the Chronic Illness
& Disability Payment System (CDPS) (35) risk score, which consists of 17 distinct disease categories that
include physical and psychiatric diagnoses. Next, we matched IMPACT participants to potential controls
matching on mutually exclusive SUD categories. For example, we matched patients with co-occurring
opioid and methamphetamine use only to controls with co-occurring opioids and methamphetamine
use. This allowed us to account for polysubstance use. Then, within each exactly matched SUD group we
nearest-neighbor matched each IMPACT patient to two controls, without replacement, based on
propensity score.

Measures:
The primary outcome, was the Healthcare Effectiveness Data and Information Set (HEDIS) National
Committee for Quality Assurance (NCQA) definition of post-discharge SUD treatment engagement, (36)
which includes two or more of the following occurring on at least two separate days within 34 days of
discharge: 1) a filled prescription for medication treatment (e.g. buprenorphine), 2) a procedure code
for SUD treatment (e.g. methadone administration at an opioid treatment program, behavioral
treatment for stimulant use disorder), or 3) a clinic visit with an SUD ICD9 or 10 code (appendix). Filled
prescriptions were limited to FDA-approved medications for SUD (excluding medication for tobacco use
disorder). Medications dispensed from a hospital pharmacy at the time of discharge (for example, a
bridging prescription for buprenorphine) do not appear in Oregon Medicaid claims; instead, they are
included as part of the inpatient admission. In general, IMPACT’s practice is to provide a 7-14 day bridge
prescription for buprenorphine, and up to 28 days for oral naltrexone or acamprosate at hospital
discharge. A single prescription in the 34-days after discharge or one-time administration of a longacting injectable medication would appear as a single encounter and not meet criteria for HEDIS
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treatment engagement. Both of these factors might lead to an under-estimate of post-hospital SUD
treatment engagement using our primary outcome.

Covariates adjusted for in the final model included SUD treatment engagement in the 34 days prior to
hospitalization, SUD type (opioid SUD vs. non-opioid SUD), gender, age, race/ethnicity, Portland tricounty area residence as a surrogate marker for urban versus non-urban healthcare systems, Medicare
Severity Diagnosis-Related Group (MS-DRG) (37) category, Chronic Illness & Disability Payment System
risk score (35).

Analysis
We used multivariable logistic regression to evaluate the effect of IMPACT participation on treatment
engagement. Due to small counts for many of the MS-DRGs we collapsed them into clinically meaningful
groups with sufficient numbers to model. High prevalence of polysubstance use led to sizeable overlap
when we analyzed the effect of individual substances separately. Hence, we separated patients with any
opioid use versus others because of the existence of more effective treatment options for opioid use
disorder. Due to concerns that post-hospital treatment engagement could be driven by prior SUD
treatment, we also conducted a sensitivity analysis modeling engagement among only those patients
who had not engaged in SUD treatment in the 34 days prior to hospitalization. We performed data
management and statistical analysis using Stata version 15.1.

Role of the Funding Source:
This study was funded by the OHSU School of Medicine. Funders had no role in the design, conduct and
reporting of this study.
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RESULTS
Cases (n=208) and controls (n=416) had similar gender, race and ethnicity, rural residence, age, and
mean CDPS risk score distribution (Table 1). 60.3% were male, 54.7% were 40 years or older, 29.8% had
any opioid SUD diagnosis. More cases resided in the Portland tri-county area (82.7% vs. 70.9%). More
controls had DRGs in the heterogeneous “other” category (40.1% vs. 29.3%). Only 17.2% of all patients
were engaged in treatment in the 34 days prior to hospitalization, with similar rates among IMPACT
(12.5-19.2%) and controls (12.3-16.0%). Of the 208 IMPACT patients, 31 received a discharge
prescription for buprenorphine, 14 for oral naltrexone, 8 for acamprosate, and 18 received injectable
naltrexone during hospitalization with a plan to continue. At the time of discharge, 56 had a plan to
continue methadone maintenance. At 34 days, 1 person in IMPACT and 14 people in the control group
had died.

In the primary analysis, IMPACT patients engaged in SUD treatment following discharge more frequently
than controls (38.9% vs. 23.3%, p<0.01; adjusted odds ratio [aOR] 2.15, 95% confidence interval [CI]
1.29-3.58 (Table 2). Predictably, those engaged in treatment before admission had substantially greater
odds of receiving treatment after discharge (aOR 11.95; 95% CI 6.31-22.65). A sensitivity analysis limiting
the sample to those without pre-hospital SUD treatment showed similar results, with a significant
association between IMPACT and engagement in SUD treatment (aOR 2.63, 95% CI 1.46-4.72). Patients
with opioid use disorder were more likely than those without an opioid use disorder to engage in
treatment (aOR 1.83, 95% CI 1.03-3.24).

The figure shows the unadjusted proportion of patients receiving treatment in the 6 months before
hospitalization and within the 34 days after discharge. Treatment engagement is similar in the months
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before admission and increases following discharge, more for IMPACT patients than controls (39.9% vs.
23.3%, p<.01) (Figure 2).

DISCUSSION
Hospitalized Medicaid recipients with SUD who received inpatient addiction medicine consultation had
greater odds of post-hospital SUD treatment engagement than matched controls. Few patients were
engaged in SUD care prior to hospitalization, highlighting the role of hospitalization as a reachable
moment. To our knowledge, this is most rigorously controlled study demonstrating the effectiveness of
an inpatient addiction medicine consult service in improving SUD treatment engagement, one of the
enduring gaps in the SUD treatment continuum (38).

Our study extends previous research in several important ways. First, propensity score-matched controls
provide a rigorous comparison group which alleviates potential bias due to systematic differences in
treatment groups, (39) and we also controlled for known confounders. Our work builds on a quasiexperimental study at a Boston academic medical center that compared patients who received inpatient
addiction medicine consultation with those who did not, finding that patients seen by the inpatient
consult service were more likely to report SUD treatment engagement at 30 and 90 days after discharge
(30). While promising, this study was quasi-experimental, relied on self-reported outcomes and had high
loss-to follow up (34% at 30 days, 47% at 90 days). Second, whereas earlier studies (25-27) measure
engagement as a single SUD-related encounter, ours ties hospital-initiated care to multiple post-hospital
treatment encounters using the NCQA HEDIS measure. Third, our study measured treatment
engagement state-wide across any setting, whereas prior studies measured engagement by self-report
or referral to a single SUD treatment location (25, 27). Finally, claims data provide a more reliable
measure of treatment engagement than self-report.
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Patients with opioid use disorder (OUD) had greater odds of engagement than those with non-opioid
SUD. We hypothesize that this may be due to greater uptake and effectiveness of medications for OUD
compared with non-opioid SUD, particularly for methamphetamine use disorder.

Treatment prior to admission was, unsurprisingly, associated with substantial increased odds of
treatment engagement following hospitalization. One might hypothesize that the effect of an
intervention such as IMPACT is driven by prior treatment engagement, however a sensitivity analysis
showed IMPACT had a durable effect amongst patients without prior treatment engagement. This
highlights a potential role of inpatient addiction medicine consult services in facility treatment retention
by avoiding treatment interruption during hospitalization and return to use—another major gap in the
SUD treatment continuum.

Our study has several important implications. First, hospitals can and should address SUD. Current
hospital practice, which treats acute medical problems resulting from SUD without addressing the
underlying cause, is analogous to performing an amputation for a diabetic foot infection without
providing insulin or referring to outpatient diabetes care. The finding that inpatient addiction medicine
care increases post-hospital treatment engagement further underscores the need to address SUD during
hospitalization.

In our study, only 17% of people were engaged in treatment prior to hospitalization. This is consistent
with national trends showing that only 7.7% of people with any past-year SUD received treatment (40).
Current reform efforts have focused largely on integrating addictions treatment in primary care. These
are critical reforms, and long-term success of hospital-based interventions depends on availability of
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community treatment. However, integrating SUD care in hospitals should not be overlooked. Hospitals
have potential to engage people who are not engaged in primary care, who are medically complex,
whose SUD may be particularly severe, and who may be high healthcare utilizers.

Doubling the odds of treatment engagement, with 39% of IMPACT participants engaging in post-hospital
SUD care, is important. Our outcome measure may underestimate treatment engagement. However,
the patients that did not connect to treatment warrant consideration. Not all hospitalized adults with
SUD want treatment, highlighting our continued duty to implement harm reduction practices in
hospitals and across communities. Ample evidence supports that harm reduction practices make
substance use safer and ultimately can engage people in treatment (41-44). However, some patients
may have wanted to engage in treatment and been unsuccessful because of limited transportation,
housing, criminal justice involvement, and medical illness. Hospital interventions can be catalysts for
community level change, but alone they cannot address structural barriers such as federal regulations
limiting methadone access, banning medication for opioid use disorder in jails, and the need for more
buprenorphine providers. Rural treatment access is another important consideration. Though it did not
meet the statistical threshold for significance, patients with SUD who resided in areas outside of
metropolitan Portland less commonly engaged in SUD treatment following discharge, consistent with
lack of treatment providers, transportation and other barriers that limit access to SUD care in rural
America (45, 46). Finally, medical frailty presents a significant challenge to SUD treatment engagement.
Barriers occur at the level of SUD treatment, where the physical demands of standing in line for
methadone or participating in groups can represent insurmountable barriers. And post-acute care
settings such as skilled nursing facilities (SNFs) often force people to choose physical rehabilitation or
SUD treatment (also often denying people access to SNF altogether based on a history of SUD) (26). In
this regard, hospital-based addictions medicine consult services have potential to improve SUD
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treatment retention and relapse prevention through care planning —another major gap in the SUD
treatment continuum.
Our study has several important limitations. First, claims data are collected primarily for billing and may
not accurately reflect all diagnoses. Further, claims do not include non-billable SUD services such as 12step meetings, syringe exchange services, or prescriptions dispensed on the day of discharge from a
hospital pharmacy – a common practice for IMPACT that potentially underestimates its effect. Second,
the study is not a randomized controlled trial and thus may be influenced by selection bias or unknown
confounders. Due to complexities related to when IMPACT was available across different services, we
do not have data on the total number of patients that could have been eligible for IMPACT. It is possible
that providers referred patients who would be more or less likely than controls to engage in SUD
treatment. For example, providers may have preferentially referred patients who expressed an interest
in treatment. Alternatively, providers may have referred patients who declined usual care social work
SUD referrals or who had severe medical or behavioral complications (e.g. disruptive behaviors including
active in-hospital drug use, leaving against medical advice) associated with lower likelihood of treatment
engagement. We mitigated this by 1) making IMPACT broadly inclusive (excluding only those who
refused to speak with us and reducing the risk that only motivated patients entered the study), 2)
propensity score matching, which can approximate randomization and adjust for unmeasured
confounders (47, 48), 3) adjusting for covariates and pre-hospital SUD treatment, and 4) using a
stringent outcome which may under-estimate the true effect of IMPACT. Thirds, we limited our study
population to adults with Oregon Medicaid; however, Medicaid patients comprise most hospitalized
patients with SUD (49). Fourth, this was not a blinded study, however we do not expect blinding to
affect assessment of the outcome, which was measured using administrative data. Fifth, Medicaid
claims data does not reliably include important social factors such as housing and transportation, so we
were unable to control for these. Sixth, we were unable to assess follow up among people who lost
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Medicaid insurance in the 34 days after discharge, which likely had a minimal effect, and in those who
moved out of Oregon following discharge. Because IMPACT occasionally supported people to connect
with supportive family and/or treatment out-of-state, this may have underestimated SUD engagement
in the IMPACT group. Finally, our study was performed in a single state with low racial and ethnic
diversity and was among the first states to expand Medicaid, which may limit generalizability.

Our study shows that hospitalization can be a place to initiate and engage people in SUD care, however
more research is needed to understand how to best support long-term treatment retention. Recently
hospitalized adults may have different treatment needs. Future research examining treatment retention
among recently discharged adults with SUD is warranted. This research should include those in
treatment before admission and those who initiated treatment during hospitalization.

Future research should define which components of hospital-based addictions care such as IMPACT are
most important: for example, for which patients with opioid use disorder is a physician prescribing
medication or linking to community treatment sufficient, and which patients need peer support or social
work intervention? Additional research is also needed to understand how to adapt an IMPACT-model to
different settings with different resources. Finally, future research is needed to assess the effect of
hospital-based addiction medicine consultation on patient experience, SUD severity, against medical
advice discharge rates, physical health outcomes, hospital readmissions, healthcare costs, and mortality.

CONCLUSIONS:
Hospital-based addiction medicine care can improve SUD treatment engagement. National expansion of
such models represents an opportunity to address one of the enduring gaps in the SUD treatment
continuum.
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Table 1: Patient characteristics: IMPACT versus Controls
IMPACT
N=208
Characteristic

Controls
N=416

Total
N=624

P-valuea

N (%)

Prior SUD treatment

b

37 (17.8)

70 (16.8)

107 (17.2)

0.76

146 (70.2)
62 (29.8)
127 (61.1)
102 (49.0)
106 (51.0)
160 (76.9)

292 (70.2)
124 (29.8)
249 (59.9)
181 (43.5)
235 (56.5)
341 (82.0)

438 (70.2)
186 (29.8)
376 (60.3)
283 (45.4)
341 (54.7)
501 (80.3)

1.00
1.00
0.77
0.19

172 (82.7)

295 (70.9)

467 (74.8)

<0.01

MS-DRG Category
Alcohol & related complications
Endocarditis, osteomyelitis, sepsis
Skin & soft tissue infections
Non-valvular cardiovascular
Orthopedic/Joint
Other

44 (21.2)
65 (31.3)
16 (7.7)
13 (6.3)
9 (4.3)
61 (29.3)

86 (20.7)
116 (27.9)
10 (2.4)
17 (4.1)
20 (4.8)
167 (40.1)
Mean (SD)

130 (20.8)
181 (29.0)
26 (4.2)
30 (4.8)
29 (4.7)
228 (36.5)

0.01

CDPS Risk Scoreg

4.1 (2.5)

4.08 (2.1)

4.09 (2.2)

0.93

SUD Type
Non-opioid SUDc
Any opioid SUDd
Male
Age 18-39 years
Age 40-64 years
White Non-Hispanic
Portland tri-county area

e

0.14

f

a

We used χ2 for categorical variables and T-test for CDPS risk score
Prior treatment defined as ≥ 2 encounters for SUD treatment on 2 separate days in 34 days before
admission. Codes used to define SUD treatment encounters are detailed in the appendix and include 1)
a filled prescription for medication treatment, 2) a procedure code for SUD treatment, or 3) a clinic visit
with an SUD ICD9 or 10 code.
c
Includes alcohol alone, stimulant alone, alcohol + stimulant, other
d
Includes opioids alone, opioids + alcohol, opioids + stimulant, opioids + alcohol + stimulant
e
Clackamas, Multnomah, and Washington counties
f
Medicare Severity Diagnosis Related Group (MS-DRG)
g
Chronic Illness & Disability Payment System (CDPS), continuous variable
Abbreviations: IMPACT, Improving Addiction Care Team; SUD, substance use disorder
b
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Table 2: Model results: Patient characteristics associated with treatment engagement
Unadjusted analyses

Characteristic
Control
IMPACT
No prior SUD treatmentc
Prior SUD treatment
Non-opioid SUDd
SUD Type
Any opioid SUDe
Gender
Female
Male
18-39
Age
(years)
40-64
Other
Race &
Ethnicity White Non-Hispanic
Region
Non tri-county area
Portland tri-county areaf

MS-DRG
Categoryg

Alcohol & related complications
Endocarditis, osteomyelitis, sepsis
Skin & soft tissue infections
Non-valvular cardiovascular
Orthopedic/Joint
Other

Adjusted analyses

Engaged in
Treatmenta
N
(%)
97
(23.3)
81
(38.9)

Not engaged
in Treatment
N
(%)
349
(76.7)
127
(61.1)

517
107
186
438
248
376
283
341
123
501
157

101
77
36
142
73
105
83
95
38
140
27

(19.5)
(72.0)
(19.4)
(32.4)
(29.4)
(27.9)
(29.3)
(27.9)
(30.9)
(27.9)
(17.2)

416
30
150
296
175
271
200
246
85
361
130

467
130
181
26
30
29
228

151
35
54
12
13
6
58
4.04

Total
N
416
208

CDPS Risk Scoreh

aORb

95% CI

Ref.
2.15

1.29

(80.5)
(28.0)
(80.6)
(67.58)
(70.6)
(72.1)
(70.7)
(72.1)
(69.1)
(72.1)
(82.8)

Ref.
12.12
Ref.
1.83
Ref.
1.05
Ref.
0.83
Ref.
0.92
Ref.

6.44 22.82
1.03 3.24
0.63 1.74
0.48 1.40
0.53 1.62
-

(32.3) 316
(26.9)
95
(29.8) 127
(46.2)
14
(43.3)
17
(20.7)
23
(25.4) 170
Mean (SD)

(67.7)
(73.1)
(70.2)
(53.8)
(56.7)
(79.3)
(74.6)

1.74
Ref.
1.19
2.36
2.07
0.49
0.98

0.90
0.62
0.88
0.80
0.12
0.49

3.34
2.28
6.32
5.36
2.02
1.94

(2.1)

(2.3)

1.05

0.93

1.19

4.11

3.58

a

Treatment defined as ≥ 2 encounters for SUD treatment on 2 separate days within 34 days of discharge;
Healthcare Effectiveness Data and Information Set (HEDIS) measure
b
Adjusted Odds Ratio (OR), adjusted for all variables in Table 2.
c

Prior Treatment defined as ≥ 2 encounters for SUD treatment on 2 separate days in 34 days before admission

d

Includes alcohol alone, stimulant alone, alcohol + stimulant, other

e

Includes opioids alone, opioids + alcohol, opioids + stimulant, opioids + alcohol + stimulant

f

Clackamas, Multnomah, and Washington counties

g

Medicare Severity Diagnosis Related Group (MS-DRG)

h

Chronic Illness & Disability Payment System (CDPS), continuous variable
Abbreviations: IMPACT, Improving Addiction Care Team; SUD, substance use disorder
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Figure 1. IMPACT participant flow diagram.
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Figure 2.

Legend: Substance Use Disorder Treatment engagement over time, comparing IMPACT and controls.
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